Abstract
The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.
| Original language | English |
|---|---|
| Pages (from-to) | 5999-6001 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 23 |
| Issue number | 20 |
| DOIs | |
| Publication status | Published - Oct 15 2017 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
On OX40 and PD-1 combination : Why should OX40 be first in sequence? / Colombo, Mario P.
In: Clinical Cancer Research, Vol. 23, No. 20, 15.10.2017, p. 5999-6001.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - On OX40 and PD-1 combination
T2 - Why should OX40 be first in sequence?
AU - Colombo, Mario P.
PY - 2017/10/15
Y1 - 2017/10/15
N2 - The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.
AB - The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence.
UR - http://www.scopus.com/inward/record.url?scp=85031497561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031497561&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-17-2332
DO - 10.1158/1078-0432.CCR-17-2332
M3 - Review article
AN - SCOPUS:85031497561
VL - 23
SP - 5999
EP - 6001
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 20
ER -